CLEVIPREX® (clevidipine) has individualized, titratable dosing and administration


Learn about CLEVIPREX® (clevidipine) titratable dosing

Low-volume, non-weight-based dosing1

  • Administered intravenously by a dedicated central or a dedicated peripheral line
  • Single-use parenteral emulsion* that contains 0.005% EDTA to inhibit the rate of growth of microorganisms for up to 12 hours
  • Metabolized by esterases in the blood and extravascular tissues
    • Elimination is unlikely to be affected by hepatic or renal dysfunction

*CLEVIPREX contains approximately 0.2g of lipid per mL (2.0 kcal).

50 mL and 100 mL CLEVIPREX single-use vials

Dosage forms and strengths

  • 50 mL and 100 mL single-use vials
  • Concentration: 0.5 mg/mL

Individualized, titratable administration1

Initiate Icon

Initiate

  • Initiate intravenous CLEVIPREX infusion at 1–2 mg/hr (2–4 mL/hr)
    • This includes patients with abnormal hepatic function and moderate to severe renal impairment
  • Individualize dosage depending on the response of the patient and the BP goal
  • Most patients were treated with maximum doses of 16 mg/hr or less
Cleviprex Dosing Calculator
1 mg/hr
2 mL/hr
2 mg/hr
4 mL/hr
4 mg/hr
8 mL/hr
6 mg/hr
12 mL/hr
...
...
32 mg/hr
64 mL/hr
mg/hr

Must enter a whole number.

Please enter a whole number between 1‑32.

mL/hr

Must enter a whole number.

Please enter an even number between 2‑64.

Titrate Icon

Titrate

  • Dose may be doubled every 90 seconds initially
  • As BP approaches goal:
    • Increase dose by less than double
    • Lengthen time between dose adjustments to every 5–10 minutes
  • An approximately 1–2 mg/hr (2–4 mL/hr) increase will generally produce an additional 2–4 mmHg decrease in SBP
  • Most patients achieve desired therapeutic response at 4–6 mg/hr (8–12 mL/hr)
    • Severe hypertension may require doses up to 32 mg/hr (64 mL/hr), but there is limited experience at this dose rate

Monitor Icon

Monitor

  • Monitor blood pressure and heart rate continually during infusion, and then until vital signs are stable
  • Patients who receive prolonged CLEVIPREX infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped. These patients may need follow-up adjustments in BP control

Optimizing CLEVIPREX administration1

Before Administration

During Administration

  • Maintain strict aseptic technique
  • Inspect package and bottle for any defects and bottle contents for particulate matter, discoloration, or contaminants; do not use if contamination is suspected
  • Invert vial gently several times before use to ensure uniformity of the emulsion
  • Once stopper is punctured, use within 12 hours and discard any unused portion
  • Because CLEVIPREX is a low-volume infusion, it is crucial to prime the IV tubing and check for dead space
  • Manage lack of response
    • Ensure CLEVIPREX is getting to the patient by checking for dead space
    • Individual patient response may vary
  • Note rapid onset and offset of CLEVIPREX when changing the IV set or vial

Watch the CLEVIPREX dosing and administration video

Watch the whole video, or select a chapter for more specific information.

(11:18)

The CLEVIPREX dosing and administration guide

Use this guide as a quick reference to help with CLEVIPREX dosing and administration.

Reference Guide of CLEVIPREX

Transitioning off CLEVIPREX

Learn what to consider when transitioning patients off CLEVIPREX.


Stroke Guidelines

The 2018 AHA/ASA AIS Guidelines now include CLEVIPREX.2